Search the Community
Showing results for tags 'riociguat'.
Found 1 result
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers (SSc-DU). In participants with SSc-DU, treatment with riociguat did not reduce the number of DU net burden compared with placebo at 16 weeks. PubMed, Arthritis Res Ther, 2019 Sep 3;21(1):202. (Also see Treatments for Digital Ulcers and Clinical Trials: Completed, Negative Results) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.